Literature DB >> 3813650

PUVA therapy damages psoriatic and normal lymphoid cells within milliseconds.

F Böhm, H Meffert, E Bauer.   

Abstract

Results of previous investigations have indicated that photochemotherapy (PUVA) attacks membranes of target cells. Using the combination of a stopped-flow technique and laser irradiation we were able to prove that the fast PUVA effect is explainable solely by the membrane damage. Lymphoid cells of healthy persons or psoriatics were taken, within 1 ms mixed with 8-methoxy-psoralen (8-MOP) at concentrations of 1.0, 0.1, and 0.5 microgram/ml, and then irradiated by a 337-nm laser pulse (0.5 mJ/cm2) lasting some picoseconds. Approximately 1 ms after administration of 8-MOP to the cell surface at least 10% of the cells were damaged, as could be judged using the standard trypan blue exclusion test. This happened at 8-MOP concentrations of 1.0 or 0.1 microgram/ml plus laser irradiation, but a concentration of 0.05 microgram/ml 8-MOP plus laser exposure did not cause any effect within 8 ms after mixing. There was no difference between using lymphoid cells from healthy persons or from psoriatics. The fact that only a very short time is necessary before cell damage occurs means that, as far as the fast PUVA effect is concerned, a photochemical reaction involving nuclear DNA can be discounted.

Entities:  

Mesh:

Year:  1986        PMID: 3813650     DOI: 10.1007/bf00404352

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  15 in total

1.  [Photochemotherapy of psoriasis using 8-methoxypsoralen and UVA. II. Binding of the photosensitizator to protein].

Authors:  H Meffert; W Diezel; W Günther; N Sönnichsen
Journal:  Dermatol Monatsschr       Date:  1976-11

2.  [Cytotoxic effect of photochemotherapy on isolated keratinocyte fractions].

Authors:  F Böhm; H Meffert; N Sönnichsen
Journal:  Dermatol Monatsschr       Date:  1986

3.  Effects of 8-methoxypsoralen and ultraviolet radiation on human lymphoid cells in vitro.

Authors:  K H Kraemer; H L Waters; L F Cohen; N C Popescu; S C Amsbaugh; J A DiPaolo; D Glaubiger; O L Ellingson; R E Tarone
Journal:  J Invest Dermatol       Date:  1981-02       Impact factor: 8.551

4.  Normal and psoriatic keratinocytes and fibroblasts compared in culture.

Authors:  H P Baden; J Kubilus; M J Macdonald
Journal:  J Invest Dermatol       Date:  1981-01       Impact factor: 8.551

5.  [Destruction of peripheral lymphocytes by 8-MOP and UVA].

Authors:  H Meffert; F Böhm; N Sönnichsen
Journal:  Dermatol Monatsschr       Date:  1980-04

6.  [Is stimulated singlet oxygen involved in the PUVA therapy effect? The effect of heavy water on membrane damage and formation of free radicals after the effect of 8-MOP and UVA on human lymphocytes].

Authors:  H Meffert; F Böhm; B Röder; N Sönnichsen
Journal:  Dermatol Monatsschr       Date:  1982-06

7.  [Membrane damage of human lymphocytes caused by PUVA].

Authors:  F Böhm; H Meffert
Journal:  Dermatol Monatsschr       Date:  1981-02

8.  [Low-level chemiluminescence measurement of the binding of 8-methoxypsoralen to protein and to lymphocytic surfaces (author's transl)].

Authors:  B Lange; H Meffert; F Böhm
Journal:  Dermatol Monatsschr       Date:  1980-09

9.  Effects of in vitro PUVA on human leukocyte function.

Authors:  A Bredberg; A Forsgren
Journal:  Br J Dermatol       Date:  1984-08       Impact factor: 9.302

10.  Sister chromatid exchange frequency in human epidermal cells in culture treated with 8-methoxypsoralen and long-wave UV radiation.

Authors:  M R West; M Johansen; M J Faed
Journal:  J Invest Dermatol       Date:  1982-01       Impact factor: 8.551

View more
  1 in total

1.  Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing.

Authors:  Britt Van Aelst; Rosalie Devloo; Pierre Zachée; Ruben t'Kindt; Koen Sandra; Philippe Vandekerckhove; Veerle Compernolle; Hendrik B Feys
Journal:  J Biol Chem       Date:  2016-09-29       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.